pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
pharmaceutical investing Positive Regulatory News from Two Pharmaceutical Companies Triggers Share Price Increases
Maritime Resources: A Low-risk Path to Gold Production in One of the World’s Top Mining Jurisdictions
Homerun Resources Inc. Announces New Homerun Energy Website and "The Hub" AI-Powered Platform for Energy Management